Browsing by Author "Zhou, Libing"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Molybdenum disulfide nanoflowers mediated anti-inflammation macrophage modulation for spinal cord injury treatment
    (Elsevier, 2019-08) Sun, Guodong; Yang, Shuxian; Cai, Huaihong; Shu, Yijin; Han, Qi; Wang, Baocheng; Li, Zhizhong; Zhou, Libing; Gao, Qingsheng; Yin, Zhinan; Neurological Surgery, School of Medicine
    Spinal cord injury (SCI) can cause locomotor dysfunctions and sensory deficits. Evidence shows that functional nanodrugs can regulate macrophage polarization and promote anti-inflammatory cytokine expression, which is feasible in SCI immunotherapeutic treatments. Molybdenum disulfide (MoS2) nanomaterials have garnered great attention as potential carriers for therapeutic payload. Herein, we synthesize MoS2@PEG (MoS2 = molybdenum disulfide, PEG = poly (ethylene glycol)) nanoflowers as an effective carrier for loading etanercept (ET) to treat SCI. We characterize drug loading and release properties of MoS2@PEG in vitro and demonstrate that ET-loading MoS2@PEG obviously inhibits the expression of M1-related pro-inflammatory markers (TNF-α, CD86 and iNOS), while promoting M2-related anti-inflammatory markers (Agr1, CD206 and IL-10) levels. In vivo, the mouse model of SCI shows that long-circulating ET-MoS2@PEG nanodrugs can effectively extravasate into the injured spinal cord up to 96 h after SCI, and promote macrophages towards M2 type polarization. As a result, the ET-loading MoS2@PEG administration in mice can protect survival motor neurons, thus, reducing injured areas at central lesion sites, and significantly improving locomotor recovery. This study demonstrates the anti-inflammatory and neuroprotective activities of ET-MoS2@PEG and promising utility of MoS2 nanomaterial-mediated drug delivery.
  • Thumbnail Image
    Item
    Surgical intervention combined with weight-bearing walking training promotes recovery in patients with chronic spinal cord injury: a randomized controlled study
    (Wolters Kluwer, 2024) Zhu, Hui; Guest, James D.; Dunlop, Sarah; Xie, Jia-Xin; Gao, Sujuan; Luo, Zhuojing; Springer, Joe E.; Wu, Wutian; Young, Wise; Poon, Wai Sang; Liu, Song; Gao, Hongkun; Yu, Tao; Wang, Dianchun; Zhou, Libing; Wu, Shengping; Zhong, Lei; Niu, Fang; Wang, Xiaomei; Liu, Yansheng; So, Kwok-Fai; Xu, Xiao-Ming; Neurological Surgery, School of Medicine
    For patients with chronic spinal cord injury, the conventional treatment is rehabilitation and treatment of spinal cord injury complications such as urinary tract infection, pressure sores, osteoporosis, and deep vein thrombosis. Surgery is rarely performed on spinal cord injury in the chronic phase, and few treatments have been proven effective in chronic spinal cord injury patients. Development of effective therapies for chronic spinal cord injury patients is needed. We conducted a randomized controlled clinical trial in patients with chronic complete thoracic spinal cord injury to compare intensive rehabilitation (weight-bearing walking training) alone with surgical intervention plus intensive rehabilitation. This clinical trial was registered at ClinicalTrials.gov (NCT02663310). The goal of surgical intervention was spinal cord detethering, restoration of cerebrospinal fluid flow, and elimination of residual spinal cord compression. We found that surgical intervention plus weight-bearing walking training was associated with a higher incidence of American Spinal Injury Association Impairment Scale improvement, reduced spasticity, and more rapid bowel and bladder functional recovery than weight-bearing walking training alone. Overall, the surgical procedures and intensive rehabilitation were safe. American Spinal Injury Association Impairment Scale improvement was more common in T7–T11 injuries than in T2–T6 injuries. Surgery combined with rehabilitation appears to have a role in treatment of chronic spinal cord injury patients.